112 related articles for article (PubMed ID: 10037176)
1. Distinct clinical and laboratory activity of two recombinant interleukin-2 preparations.
Hank JA; Surfus J; Gan J; Albertini M; Lindstrom M; Schiller JH; Hotton KM; Khorsand M; Sondel PM
Clin Cancer Res; 1999 Feb; 5(2):281-9. PubMed ID: 10037176
[TBL] [Abstract][Full Text] [Related]
2. Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo.
Redlinger RE; Mailliard RB; Lotze MT; Barksdale EM
J Pediatr Surg; 2003 Mar; 38(3):301-7; discussion 301-7. PubMed ID: 12632339
[TBL] [Abstract][Full Text] [Related]
3. Differential quantitative effects of interleukin (IL)-2 and IL-15 on cytotoxic activity and proliferation by lymphocytes from patients receiving in vivo IL-2 therapy.
de Jong JL; Farner NL; Javorsky BR; Lindstrom MJ; Hank JA; Sondel PM
Clin Cancer Res; 1998 May; 4(5):1287-96. PubMed ID: 9607589
[TBL] [Abstract][Full Text] [Related]
4. Comparative evaluation of multiple lymphoid and recombinant human interleukin-2 preparations.
Thurman GB; Maluish AE; Rossio JL; Schlick E; Onozaki K; Talmadge JE; Procopio AD; Ortaldo JR; Ruscetti FW; Stevenson HC
J Biol Response Mod; 1986 Feb; 5(1):85-107. PubMed ID: 3514800
[TBL] [Abstract][Full Text] [Related]
5. Expression and possible function of IL-2 and IL-15 receptors on human uveal melanoma cells.
He YG; Mayhew E; Mellon J; Niederkorn JY
Invest Ophthalmol Vis Sci; 2004 Dec; 45(12):4240-6. PubMed ID: 15557426
[TBL] [Abstract][Full Text] [Related]
6. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
7. In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy.
Tomala J; Chmelova H; Mrkvan T; Rihova B; Kovar M
J Immunol; 2009 Oct; 183(8):4904-12. PubMed ID: 19801515
[TBL] [Abstract][Full Text] [Related]
8. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
9. Depressed in vitro T cell responses concomitant with augmented interleukin-2 responses by lymphocytes from cancer patients following in vivo treatment with interleukin-2.
Hank JA; Sosman JA; Kohler PC; Bechhofer R; Storer B; Sondel PM
J Biol Response Mod; 1990 Feb; 9(1):5-14. PubMed ID: 2181071
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer.
Shah MH; Freud AG; Benson DM; Ferkitich AK; Dezube BJ; Bernstein ZP; Caligiuri MA
Clin Cancer Res; 2006 Jul; 12(13):3993-6. PubMed ID: 16818697
[TBL] [Abstract][Full Text] [Related]
11. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy of murine sarcomas with interleukin 2. II. Activation of killer cells by human recombinant IL-2.
Indrová M; Bubeník J; Toulcová A
Folia Biol (Praha); 1986; 32(6):392-8. PubMed ID: 3492397
[TBL] [Abstract][Full Text] [Related]
13. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
[TBL] [Abstract][Full Text] [Related]
14. Synergistic proliferation and activation of natural killer cells by interleukin 12 and interleukin 18.
Lauwerys BR; Renauld JC; Houssiau FA
Cytokine; 1999 Nov; 11(11):822-30. PubMed ID: 10547269
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-gamma production, and expansion of natural killer cells.
Son YI; Dallal RM; Mailliard RB; Egawa S; Jonak ZL; Lotze MT
Cancer Res; 2001 Feb; 61(3):884-8. PubMed ID: 11221875
[TBL] [Abstract][Full Text] [Related]
16. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
17. In vivo antitumor activity of interleukin 21 mediated by natural killer cells.
Wang G; Tschoi M; Spolski R; Lou Y; Ozaki K; Feng C; Kim G; Leonard WJ; Hwu P
Cancer Res; 2003 Dec; 63(24):9016-22. PubMed ID: 14695220
[TBL] [Abstract][Full Text] [Related]
18. Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer.
van der Vliet HJ; Koon HB; Yue SC; Uzunparmak B; Seery V; Gavin MA; Rudensky AY; Atkins MB; Balk SP; Exley MA
Clin Cancer Res; 2007 Apr; 13(7):2100-8. PubMed ID: 17404092
[TBL] [Abstract][Full Text] [Related]
19. [Synergistic role between rhIL-2 and adriamycin long circulating temperature-sensitive liposome in targeting therapy on tumor].
Dong LF; Mei HS; Song SX; Lu ZJ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 May; 21(3):296-300. PubMed ID: 15862144
[TBL] [Abstract][Full Text] [Related]
20. Recombinant interleukin-2: a biological response modifier.
Kintzel PE; Calis KA
Clin Pharm; 1991 Feb; 10(2):110-28. PubMed ID: 2009728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
